Intensity Therapeutics (NASDAQ:INTS – Get Free Report) issued its earnings results on Thursday. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.10), FiscalAI reports.
Here are the key takeaways from Intensity Therapeutics’ conference call:
- Intensity ended the quarter with $8.5 million in cash and expects operating cash burn of about $1 million per month in Q4; it may continue raising capital through its ATM and other financing. Funding is gating the pace of enrollment and site activations, particularly for INVINCIBLE-3.
- In INVINCIBLE-4, preliminary results showed a pathological complete response in 71% of patients receiving INT230-6 plus standard care, versus 42% with standard care alone; all seven INT230-6 patients had tumor necrosis. Management emphasized the sample is very small, and an independent safety review is assessing whether the revised dosing regimen resolved prior localized skin issues.
- INVINCIBLE-3 enrollment has restarted at a limited number of U.S. sites, but no patients had yet been randomized; management expects to begin with roughly 10 enrolling sites, with expansion dependent on funding. The study will use central CT review and Choi density-based criteria to assess progression, while overall survival remains the endpoint.
- Management said business-development discussions with multinational and regional companies are ongoing, with interest in either or both clinical programs, but described the talks as early-stage. Potential arrangements could include licensing or partner funding, but no agreement was announced.
Intensity Therapeutics Trading Down 3.2%
INTS stock traded down $0.10 during midday trading on Friday, hitting $3.00. 15,416 shares of the company’s stock were exchanged, compared to its average volume of 20,049. Intensity Therapeutics has a 1-year low of $2.80 and a 1-year high of $15.00. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $9.78 million, a PE ratio of -0.84 and a beta of 2.78. The business has a 50-day simple moving average of $3.63 and a two-hundred day simple moving average of $5.10.
Wall Street Analysts Forecast Growth
INTS has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Monday, October 19th. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Finally, HC Wainwright upped their price objective on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.00.
Get Our Latest Stock Analysis on Intensity Therapeutics
Intensity Therapeutics Company Profile
Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.
The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.
Read More
- Five stocks we like better than Intensity Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
